Guan Mei, Zhou Yan-Ping, Sun Jin-Lu, Chen Shu-Chang
Department of Oncology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
Department of Allergy, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
Biomed Res Int. 2015;2015:428169. doi: 10.1155/2015/428169. Epub 2015 May 5.
In 1997, the first monoclonal antibody (MoAb), the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug administration for use in cancer patients. Since then, the panel of MoAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has continued to expand, currently encompassing a stunning amount of 20 distinct molecules for 11 targets. We provide a brief scientific background on the use of MoAbs in cancer therapy, review all types of monoclonal antibodies-related adverse events (e.g., allergy, immune-related adverse events, cardiovascular adverse events, and pulmonary adverse events), and discuss the mechanism and treatment of adverse events.
1997年，首个单克隆抗体（MoAb）——嵌合抗CD20分子利妥昔单抗，获美国食品药品监督管理局批准用于癌症患者。自那时起，经国际监管机构批准用于治疗血液系统恶性肿瘤和实体恶性肿瘤的单克隆抗体种类不断增加，目前涵盖针对11个靶点的多达20种不同分子。我们简要介绍单克隆抗体在癌症治疗中的科学背景，回顾各类与单克隆抗体相关的不良事件（如过敏、免疫相关不良事件、心血管不良事件和肺部不良事件），并讨论不良事件的发生机制及治疗方法。
